SG
Scangos George A
首席执行官
C-suiteM
内部人交易记录
首席执行官尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Discover the complete record of transactions filed by Scangos George A, 首席执行官. Insider active across 4 companies, notably Vir Biotechnology, Inc.. In total, 21 reports have been logged. Split: 0 buy · 6 sells. Total volume traded: €981k. Activity tracked since 17 February 2022. The latest transaction was filed on 19 March 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Scangos George A
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报21 总计
2,158 股@ US$111.7513.7% 占其流量Common StockSEC:0001090872-26-000036:0
1,819 股@ US$121.1815.3% 占其流量Common StockSEC:0001127602-25-009725:0
10,056 股@ US$9.45349.3% 占其流量Common StockSEC:0001628280-25-007708:0
10,964 股@ US$9.811710.5% 占其流量Common StockSEC:0001628280-25-006516:0
598,270 股0Common StockSEC:0001628280-24-043632:0
8,000 股0Common StockSEC:0001628280-24-026219:0
3,443 股@ US$145.4834.9% 占其流量Common StockSEC:0001127602-24-017078:0
1,678 股@ US$147.4817.1% 占其流量Common StockSEC:0001127602-24-010687:0
10,028 股@ US$10.04569.5% 占其流量Common StockSEC:0001628280-24-006980:0
10,878 股@ US$10.239610.5% 占其流量Common StockSEC:0001628280-24-005747:0
1,750,000 股0Common StockSEC:0001628280-23-034571:0
3,500,000 股0Common StockSEC:0001209191-23-049722:0
1,658 股@ US$136.8216.1% 占其流量Common StockSEC:0000899243-23-009227:0
12,631 股@ US$25.97331.5% 占其流量Common StockSEC:0001209191-23-013004:0
49,984 股0Common StockSEC:0001209191-23-011387:0
111,000 股0Common StockSEC:0001209191-22-023524:0
1,785 股@ US$136.8214.4% 占其流量Common StockSEC:0001127602-22-010055:0
10,024 股@ US$31.930828.7% 占其流量Common StockSEC:0001209191-22-011756:0
11,274 股Common StockSEC:0001127602-16-040395:0
5,305 股Common StockSEC:0001127602-16-040395:1
6,383 股Common StockSEC:0000939767-16-000126:0
About Scangos George A
SCANGOS GEORGE A is Président et Directeur Général. He has 21 filings, and among the sampled recent filings, the sell amount is EUR 980538, over the period from 2016-01-05 to 2026-03-23. His recent filings concern Agilent Technologies, INC. and Vir Biotechnology, Inc., with transaction nature shown as Attribution.